The European journal of cardiovascular medicine最新文献

英文中文

INTRAMYOCARDIAL STEM CELL TRANSPLANTATION IN CARDIAC SURGERY: FROM PRECLINICAL BACKGROUNDS TO THE PERFECT TRIAL 心脏手术中心肌内干细胞移植:从临床前背景到完美试验

The European journal of cardiovascular medicine

Pub Date : 2011-02-20 DOI: 10.5083/EJCM.20424884.20

P. Donndorf, Prof. Dr. med. Gustav Steinhoff

After initial reports of successful stem cell delivery to the injured heart, the clinical feasibility and safety of this new therapeutic strategy has been established, thereby focusing on the treatment of ischemic heart disease. Over 3000 patients with either recent myocardial infarction or chronic ischemic heart failure have been treated so far by means of interventional cardiology and cardiac surgery. Prospective clinical studies could prove the safety of both interventional intracoronary stem cell injection as well as surgical intramyocardial cell injection (4, 5).

在干细胞成功移植到受损心脏的初步报道之后，这种新的治疗策略的临床可行性和安全性已经确立，从而将重点放在缺血性心脏病的治疗上。迄今为止，通过介入心脏病学和心脏外科手术治疗了3000多例近期心肌梗死或慢性缺血性心力衰竭患者。前瞻性临床研究可以证明介入冠状动脉内干细胞注射和手术心肌内细胞注射的安全性(4,5)。

引用次数: 2

Malign Asystole During Head-up Tilt Test: A Case Report and Overview. 平视倾斜试验中恶性心脏骤停一例报告及综述。

The European journal of cardiovascular medicine

Pub Date : 2011-02-01 DOI: 10.5083/ejcm.20424884.22

Yahya Islamoglu, Musa Cakici, Hayri Alici, Vedat Davutoglu

引用次数: 0

Malign Asystole During Head-up Tilt Test: A Case Report and Overview. 平视倾斜试验中恶性心脏骤停一例报告及综述。

The European journal of cardiovascular medicine

Pub Date : 2011-02-01 DOI: 10.1016/S0167-5273(11)70482-X

Y. Islamoğlu, M. Çakıcı, H. Alıcı, V. Davutoglu

引用次数: 2

Effective Lipid-lowering Therapy in High-risk Patients 高危患者的有效降脂治疗

The European journal of cardiovascular medicine

Pub Date : 2011-01-25 DOI: 10.5083/EJCM.20424884.211

J. Kastelein, B. Arsenault, J. Tardif

引用次数: 0

Cor Triatriatum Sinistrum: Classification and Imaging Modalities. 心房三裂:分类和成像方式。

The European journal of cardiovascular medicine

Pub Date : 2011-01-01 DOI: 10.5083/ejcm.20424884.21

Pierre Nagib Nassar, Righab Haidar Hamdan

Cor Triatriatum Sinister is a rare congenital abnormality, usually diagnosed in childhood; few cases remain asymptomatic and are diagnosed in adulthood. In this review article we focus on classification and etiologies, clinical manifestations, novel diagnostic modalities and treatment of Cor triatriatum Sinister.

三心房畸形是一种罕见的先天性畸形，通常在儿童时期诊断;少数病例仍然无症状，并在成年后被诊断出来。在这篇综述文章中，我们的重点是分类和病因，临床表现，新的诊断方式和治疗三房心险恶。

引用次数: 83

Emerging Risk Stratification in Syncope. 晕厥新出现的危险分层。

The European journal of cardiovascular medicine

Pub Date : 2010-07-01 DOI: 10.5083/ejcm.20424884.11

S V Jamalyan, L A Khachatryan

引用次数: 3

Inherited Cardiac Diseases: Preimplantation Genetic Diagnosis - An Attractive Alternative to Prenatal Diagnosis 遗传性心脏病:植入前遗传学诊断-产前诊断的一个有吸引力的选择

The European journal of cardiovascular medicine

Pub Date : 2010-06-20 DOI: 10.5083/EJCM.20424884.09

J. Theilade, M. Duno, S. Ziebe, H. Bundgaard

引用次数: 0

The Clinical Benefit of Omega-3 PUFA Ethyl Esters Omega-3 PUFA乙酯的临床益处

The European journal of cardiovascular medicine

Pub Date : 2010-06-20 DOI: 10.5083/ejcm.20424884.07

M. Cowie

Chronic heart failure, a syndrome of cardiac dysfunction associated with breathlessness, effort intolerance and fluid retention, affects 1-2% of the population. The most frequent cause is impairment of systolic function of the left ventricle, usually due to coronary artery disease. Hypertension or diabetes often co-exist. Treatment of heart failure (HF) is centred on correction of any reversible pathology and antagonism of the intense neurohormonal activation triggered by the cardiac dysfunction. This is achieved by angiotensin converting enzyme inhibitors (or angiotensin receptor blockers), beta-blockers and in more severe cases, an aldosterone antagonist. The prognosis of HF remains poor – with a first year mortality of over 30%, reducing to 10% per annum thereafter. Death is usually due to either progressive pump failure or sudden death, which is presumably arrhythmic in origin. A randomised double-blind controlled trial of 1g daily of omega-3 polyunsaturated fatty acids (PUFA) ethyl esters in almost 7000 patients with symptomatic chronic heart failure of any cause reported a 9% relative risk reduction in mortality (P=0.04) and 8% relative risk reduction in mortality or cardiovascular hospitalisation (P=0.009)(GISSI-HF). In absolute terms, 56 patients need to be treated for 3.9 years to prevent one death. International guidelines recommend the prescription of 1g daily of n-3 PUFA as an adjuvant to secondary prevention in patients after myocardial infarction (based on the results of GISSI-Prevenzione, published in 1999) and for those with hypertriglyceridaemia, but are likely to be updated to recommend this therapy for patients with heart failure also.

慢性心力衰竭是一种与呼吸困难、努力不耐受和液体潴留相关的心功能障碍综合征，影响1-2%的人口。最常见的原因是左心室收缩功能受损，通常由冠状动脉疾病引起。高血压和糖尿病经常共存。心力衰竭(HF)的治疗集中在纠正任何可逆性病理和拮抗由心功能障碍引发的强烈神经激素激活。这是通过血管紧张素转换酶抑制剂(或血管紧张素受体阻滞剂)，受体阻滞剂和更严重的情况下醛固酮拮抗剂实现的。心衰的预后仍然很差，第一年死亡率超过30%，此后每年死亡率降至10%。死亡通常是由于进行性泵衰竭或猝死，这可能是源于心律失常。在一项随机双盲对照试验中，近7000例任何原因的症状性慢性心力衰竭患者每天服用1g omega-3多不饱和脂肪酸(PUFA)乙酯，死亡率相对风险降低9% (P=0.04)，死亡率或心血管住院相对风险降低8% (P=0.009)(gisi - hf)。从绝对值来看，56名患者需要接受3.9年的治疗才能避免1人死亡。国际指南推荐每日1g n-3 PUFA处方，作为心肌梗死后患者和高甘油三酯血症患者二级预防的辅助治疗(基于1999年发表的gisi - prevenzione的结果)，但可能会更新为心力衰竭患者推荐这种治疗方法。

{"title":"The Clinical Benefit of Omega-3 PUFA Ethyl Esters","authors":"M. Cowie","doi":"10.5083/ejcm.20424884.07","DOIUrl":"https://doi.org/10.5083/ejcm.20424884.07","url":null,"abstract":"Chronic heart failure, a syndrome of cardiac dysfunction associated with breathlessness, effort intolerance and fluid retention, affects 1-2% of the population. The most frequent cause is impairment of systolic function of the left ventricle, usually due to coronary artery disease. Hypertension or diabetes often co-exist. Treatment of heart failure (HF) is centred on correction of any reversible pathology and antagonism of the intense neurohormonal activation triggered by the cardiac dysfunction. This is achieved by angiotensin converting enzyme inhibitors (or angiotensin receptor blockers), beta-blockers and in more severe cases, an aldosterone antagonist. The prognosis of HF remains poor – with a first year mortality of over 30%, reducing to 10% per annum thereafter. Death is usually due to either progressive pump failure or sudden death, which is presumably arrhythmic in origin. A randomised double-blind controlled trial of 1g daily of omega-3 polyunsaturated fatty acids (PUFA) ethyl esters in almost 7000 patients with symptomatic chronic heart failure of any cause reported a 9% relative risk reduction in mortality (P=0.04) and 8% relative risk reduction in mortality or cardiovascular hospitalisation (P=0.009)(GISSI-HF). In absolute terms, 56 patients need to be treated for 3.9 years to prevent one death. International guidelines recommend the prescription of 1g daily of n-3 PUFA as an adjuvant to secondary prevention in patients after myocardial infarction (based on the results of GISSI-Prevenzione, published in 1999) and for those with hypertriglyceridaemia, but are likely to be updated to recommend this therapy for patients with heart failure also.","PeriodicalId":75000,"journal":{"name":"The European journal of cardiovascular medicine","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2010-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5083/ejcm.20424884.07","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70860170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Review of Registry and Randomised Comparisons of Zotarolimus-eluting and Sirolimus-eluting Coronary Stents in Western Denmark 丹麦西部佐他莫司洗脱和西罗莫司洗脱冠脉支架的注册和随机比较综述

The European journal of cardiovascular medicine

Pub Date : 2010-06-20 DOI: 10.5083/EJCM.20424884.06

M. Maeng, A. Kaltoft, L. Jensen, P. Thayssen, N. Holm, E. Christiansen, L. Krusell, C. Terkelsen, S. Kristensen, H. Bøtker, J. Lassen, L. Thuesen, H. Hansen, J. Ravkilde

The safety and efficacy of coronary stents utilised for treatment of ischaemic heart disease have been extensively evaluated. In comparison with bare metal stents, first-generation drug-eluting stents more than halved the need for target lesion revascularisation (TLR). However, the long-term safety has been questioned as the first-generation drug-eluting stents seemed to be associated with a small, but increased, risk of (very) late stent thrombosis. The latter may be related to an inflammatory reaction caused by the polymer used for drug release control. The second-generation zotarolimuseluting Endeavor® stent was believed to represent a safer alternative. We present an overview of our results from a large randomised trial and a large registry, both of which compared clinical outcomes with the Endeavor® and the first-generation sirolimus-eluting Cypher® stent. Both studies indicated that the Endeavor® stent had higher risks of adverse outcomes. We discuss these data in the light of the current available data from other randomised comparisons of these two drug-eluting stents.

用于治疗缺血性心脏病的冠状动脉支架的安全性和有效性已被广泛评估。与裸金属支架相比，第一代药物洗脱支架将靶病变血运重建术(TLR)的需求减少了一半以上。然而，长期安全性一直受到质疑，因为第一代药物洗脱支架似乎与(非常)晚期支架血栓形成的风险很小，但增加了。后者可能与用于药物释放控制的聚合物引起的炎症反应有关。第二代佐他莫司洗脱Endeavor®支架被认为是一种更安全的选择。我们概述了一项大型随机试验和大型注册研究的结果，这两项研究都比较了Endeavor®和第一代西罗莫司洗脱Cypher®支架的临床结果。两项研究均表明，Endeavor®支架有较高的不良后果风险。我们根据这两种药物洗脱支架的其他随机比较的现有数据来讨论这些数据。

{"title":"Review of Registry and Randomised Comparisons of Zotarolimus-eluting and Sirolimus-eluting Coronary Stents in Western Denmark","authors":"M. Maeng, A. Kaltoft, L. Jensen, P. Thayssen, N. Holm, E. Christiansen, L. Krusell, C. Terkelsen, S. Kristensen, H. Bøtker, J. Lassen, L. Thuesen, H. Hansen, J. Ravkilde","doi":"10.5083/EJCM.20424884.06","DOIUrl":"https://doi.org/10.5083/EJCM.20424884.06","url":null,"abstract":"The safety and efficacy of coronary stents utilised for treatment of ischaemic heart disease have been extensively evaluated. In comparison with bare metal stents, first-generation drug-eluting stents more than halved the need for target lesion revascularisation (TLR). However, the long-term safety has been questioned as the first-generation drug-eluting stents seemed to be associated with a small, but increased, risk of (very) late stent thrombosis. The latter may be related to an inflammatory reaction caused by the polymer used for drug release control. The second-generation zotarolimuseluting Endeavor® stent was believed to represent a safer alternative. We present an overview of our results from a large randomised trial and a large registry, both of which compared clinical outcomes with the Endeavor® and the first-generation sirolimus-eluting Cypher® stent. Both studies indicated that the Endeavor® stent had higher risks of adverse outcomes. We discuss these data in the light of the current available data from other randomised comparisons of these two drug-eluting stents.","PeriodicalId":75000,"journal":{"name":"The European journal of cardiovascular medicine","volume":"1 1","pages":"18-22"},"PeriodicalIF":0.0,"publicationDate":"2010-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5083/EJCM.20424884.06","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70859791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug-eluting Stents in Acute Coronary Syndrome: Is There a Risk of Stent Thrombosis with Second-Generation Stents? 药物洗脱支架治疗急性冠脉综合征:第二代支架有支架血栓形成的风险吗?

The European journal of cardiovascular medicine

Pub Date : 2010-06-01 DOI: 10.5083/ejcm.20424884.10

Kamal Chitkara, Kushal Pujara

Over the past decade, the advent of drug-eluting stents (DES) has revolutionised the field of interventional cardiology by having a major impact on patient care through their efficacy in reducing the need for repeat revascularisation. A number of stents capable of delivering an anti-proliferative agent designed to prevent neointimal hyperplasia, the principal mechanism of restenosis after stenting, have been evaluated; four of these devices are currently approved by the U.S. Food and Drug Administration (FDA). Bare metal stent (BMS) and first-generation DES, such as sirolimus-eluting (SES-Cypher(®)) and paclitaxel-eluting stents (PES-Taxus(®)), have further improved results of percutaneous coronary intervention (PCI) by improving early results and reducing the risk of restenosis. However, there is currently debate on the safety of these first-generation DES, given the potential for late stent thrombosis (LST), especially after discontinuation of dual anti-platelet therapy. Second-generation DES, such as zotarolimus-eluting (ZES-Endeavor(®)) and everolimus-eluting stents (EES-Xience V(®)), are become available in the USA and/or Europe. Recently, long-term results comparing DES with BMS in patients with ST-segment-elevation MI (STEMI) have raised some questions about the long-term risks of the drug-eluting devices. It may be useful to pause, reflect for a moment, and consider some recent pertinent results regarding their wider use. This systematic review tries to provide a concise and critical appraisal of the data available to compare first and second generation stents especially to assess risk of stent thrombosis (ST) with second-generation DES.

在过去的十年中，药物洗脱支架(DES)的出现彻底改变了介入心脏病学领域，通过其减少重复血运重建需求的功效，对患者护理产生了重大影响。一些支架能够提供抗增殖剂，以防止新内膜增生，这是支架置入后再狭窄的主要机制，已经被评估;其中四种设备目前已获得美国食品和药物管理局(FDA)的批准。裸金属支架(BMS)和第一代DES，如西罗莫斯洗脱支架(SES-Cypher(®))和紫杉醇洗脱支架(PES-Taxus(®))，通过改善早期结果和降低再狭窄的风险，进一步改善了经皮冠状动脉介入治疗(PCI)的结果。然而，考虑到晚期支架血栓形成(LST)的可能性，特别是在停止双重抗血小板治疗后，目前对这些第一代DES的安全性存在争议。第二代DES，如佐他莫司洗脱支架(ees - endeavor(®))和依维莫司洗脱支架(EES-Xience V(®))，已在美国和/或欧洲上市。最近，比较DES和BMS在st段抬高型心肌梗死(STEMI)患者中的长期结果，提出了一些关于药物洗脱装置长期风险的问题。暂停一下，思考一下，考虑一下最近关于它们更广泛使用的一些相关结果，可能是有用的。本系统综述试图对第一代和第二代支架的可用数据进行简明和批判性的评估，特别是评估第二代DES的支架血栓形成(ST)风险。

{"title":"Drug-eluting Stents in Acute Coronary Syndrome: Is There a Risk of Stent Thrombosis with Second-Generation Stents?","authors":"Kamal Chitkara, Kushal Pujara","doi":"10.5083/ejcm.20424884.10","DOIUrl":"https://doi.org/10.5083/ejcm.20424884.10","url":null,"abstract":"<p><p>Over the past decade, the advent of drug-eluting stents (DES) has revolutionised the field of interventional cardiology by having a major impact on patient care through their efficacy in reducing the need for repeat revascularisation. A number of stents capable of delivering an anti-proliferative agent designed to prevent neointimal hyperplasia, the principal mechanism of restenosis after stenting, have been evaluated; four of these devices are currently approved by the U.S. Food and Drug Administration (FDA). Bare metal stent (BMS) and first-generation DES, such as sirolimus-eluting (SES-Cypher(®)) and paclitaxel-eluting stents (PES-Taxus(®)), have further improved results of percutaneous coronary intervention (PCI) by improving early results and reducing the risk of restenosis. However, there is currently debate on the safety of these first-generation DES, given the potential for late stent thrombosis (LST), especially after discontinuation of dual anti-platelet therapy. Second-generation DES, such as zotarolimus-eluting (ZES-Endeavor(®)) and everolimus-eluting stents (EES-Xience V(®)), are become available in the USA and/or Europe. Recently, long-term results comparing DES with BMS in patients with ST-segment-elevation MI (STEMI) have raised some questions about the long-term risks of the drug-eluting devices. It may be useful to pause, reflect for a moment, and consider some recent pertinent results regarding their wider use. This systematic review tries to provide a concise and critical appraisal of the data available to compare first and second generation stents especially to assess risk of stent thrombosis (ST) with second-generation DES.</p>","PeriodicalId":75000,"journal":{"name":"The European journal of cardiovascular medicine","volume":"1 2","pages":"20-24"},"PeriodicalIF":0.0,"publicationDate":"2010-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5083/ejcm.20424884.10","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29867673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

The European journal of cardiovascular medicine

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀